Actinium Pharmaceuticals - Articles and news items

FDA grants orphan drug designation to Iomab-B

Industry news / 31 March 2016 / Victoria White

Actinium’s Iomab-B is a radioimmunotherapeutic that conditions relapsed and refractory AML patients for a haematopoietic stem cell transplant…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+